Roche has shelved the pre‑clinical obesity candidate CT-173, a long‑acting PYY analogue acquired in the $2.7 billion Carmot Therapeutics buyout, because it did not meet internal ‘developability and competitiveness’ criteria before entering clinical trials.
The move is part of a broader pipeline review that saw Roche discontinue CT‑173 along with three investigational oncology drugs, redirecting resources toward programs with higher clinical and commercial potential, including Carmot’s lead obesity candidates CT‑388 and CT‑996.
On the artificial‑intelligence front, Teresa Graham, head of Roche’s pharmaceutical division, has publicly emphasized that the company is being ‘thoughtful’ about token use for AI tools, focusing on how to scale AI responsibly across research and development rather than rushing into broad adoption.
Sources:
Roche enters into a definitive merger agreement to acquire ...
Roche axes Carmot obesity asset, 3 cancer drugs in R&D ...
Roche shuffles early stage pipeline as it joins obesity rush
Roche joins race for obesity drugs with $2.7 billion Carmot deal
Roche Will Buy Obesity And Diabetes Drugmaker Carmot Therapeutics In $2.7 Billion Deal
Roche to Buy Carmot Therapeutics for Up to $3.1 Billion in ...
UPDATE: Roche muscles in on obesity market with $2.7B Carmot buy
Roche joins obesity drug chase with $2.7B deal for startup ...
Roche Culls Carmot Obesity Candidate and Three Oncology Drugs ...
Roche Lines Up $2.7B Acquisition to Join Chase for New ...
Roche's $2.7bn Acquisition of Carmot Therapeutics - MergerSight
Roche to buy Carmot for $2.7 billion
Roche to acquire obesity-focused Carmot Therapeutics for $2.7 billion